Laborie Medical Technologies has announced an investment in I-O Urology, the developer of the CarePath uroflow device.

The US Food and Drug Administration (FDA)-approved, at-home diagnostic tool, CarePath, aims to reduce urinary tract symptoms (LUTS) treatment.

Eligible for remote patient monitoring reimbursement, the system is designed to improve compliance and patient engagement, as well as standardise treatment for LUTS.

I-O Urology co-founder and CEO Britton Garrett said: “We’re eager to collaborate with Laborie, pioneers in diagnostic and therapeutic urologic healthcare.

“CarePath bridges the clinic-patient gap, offering a convenient, accessible solution for managing urological conditions in the home.”

The device has seen use in several US clinics. It aims to improve the diagnosis and management of LUTS conditions such as benign prostatic hyperplasia (BPH).

Designed for direct-to-patient, the CarePath device features embedded cellular connectivity, ensuring accurate data transmission.

This technology facilitates reliable diagnostics and enhances patient education and engagement in managing LUTS issues.  

With the device, 91% of patients revisited the clinic to discuss the CarePath Uroflow report with their provider and explore the possibility of surgical intervention.

I-O Urology's CarePath platform was made available for clinical use in 2021.

Laborie urology vice-president and general manager Tim Panciera said: “At Laborie, we strongly believe in the value of patient education as a pathway to support the restoration of patient dignity.

“The team at I-O Urology developed a state-of-the-art device with a dynamic patient ecosystem that empowers patient engagement as a superior standard of care. Our missions are closely aligned, making this a natural investment to continue accelerating Laborie’s position and expertise in the advanced diagnostics market.”